This paper is in the following e-collection/theme issue:

Formative Evaluation of Non-Ehealth Innovations (134) Alcohol Abuse, Alcoholism Prevention and Recovery (300) Depression and Mood Disorders; Suicide Prevention (1363) Engagement with and Adherence to Digital Health Interventions, Law of Attrition (491) Bipolar Disorders (56)

Published on in Vol 7 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/44059, first published .
Direct and Indirect Predictors of Medication Adherence With Bipolar Disorder: Path Analysis

Direct and Indirect Predictors of Medication Adherence With Bipolar Disorder: Path Analysis

Direct and Indirect Predictors of Medication Adherence With Bipolar Disorder: Path Analysis

Authors of this article:

Bar Cohen1 Author Orcid Image ;   Andrew Sixsmith2 Author Orcid Image ;   Ariel Pollock Star3 Author Orcid Image ;   Ophir Haglili4 Author Orcid Image ;   Norm O'Rourke3, 4, 5 Author Orcid Image
Article Authors Cited by (2) Tweetations (2) Metrics

    Original Paper

    1Goldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel

    2Science and Technology for Aging Research Institute, Simon Fraser University, Vancouver, BC, Canada

    3Department of Epidemiology, Biostatistics and Community Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel

    4Department of Psychology, Faculty of Humanities and Social Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel

    5Center for Multidisciplinary Research in Aging, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel

    Corresponding Author:

    Norm O'Rourke, PhD

    Department of Epidemiology, Biostatistics and Community Health Sciences

    Ben-Gurion University of the Negev

    Building M6, Room #308

    P.O. Box 653

    Be'er Sheva, 8421637

    Israel

    Phone: 972 8 6477301

    Email: ORourke@bgu.ac.il


    Background: Despite the efficacy of treatment and severity of symptoms, medication adherence by many with bipolar disorder (BD) is variable at best. This poses a significant challenge for BD care management.

    Objective: For this study, we set out to identify psychosocial and psychiatric predictors of medication adherence with BD.

    Methods: Using microtargeted social media advertising, we recruited an international sample of young and older adults with BD living in North America (Canada and the United States), Western Europe (eg, United Kingdom and Ireland), Australia and New Zealand (N=92). On average, participants were 55.35 (SD 9.65; range 22-73) years of age, had been diagnosed with BD 14.25 (SD 11.14; range 1-46) years ago, and were currently prescribed 2.40 (SD 1.28; range 0-6) psychotropic medications. Participants completed questionnaires online including the Morisky Medication Adherence Scale.

    Results: Medication adherence did not significantly differ across BD subtypes, country of residence, or prescription of lithium versus other mood stabilizers (eg, anticonvulsants). Path analyses indicate that alcohol misuse and subjective or perceived cognitive failures are direct predictors of medication adherence. BD symptoms, psychological well-being, and the number of comorbid psychiatric conditions emerged as indirect predictors of medication adherence via perceived cognitive failures.

    Conclusions: Alcohol misuse did not predict perceived cognitive failures. Nor did age predict medication adherence or cognitive failures. This is noteworthy given the 51-year age range of participants. That is, persons in their 20s with BD reported similar levels of medication adherence and perceived cognitive failures as those in their 60s. This suggests that perceived cognitive loss is a facet of adult life with BD, in contrast to the assumption that accelerated cognitive aging with BD begins in midlife.

    JMIR Form Res 2023;7:e44059

    doi:10.2196/44059

    Keywords

    alcohol misuse; bipolar disorder; cognitive loss; depression; hypo/mania; mania; medication adherence; mental health; path analysis; perceived cognitive failures; polypharmacy; psychiatric disorder; psychosocial 


    Background

    Bipolar disorder (BD) is a chronic mental health condition defined by cycles of depression and mania or hypomania; symptoms are often experienced concurrently [1]. With onset for most in their late teens or early 20s, adults live for many years with BD, euthymic most of the time or with subclinical symptoms.

    Pharmacotherapy is the first line of treatment for BD [2,3], generally beginning with a mood stabilizer (eg, lithium or anticonvulsants). Antidepressants, antipsychotics, anxiolytics, and hypnotics are also commonly prescribed to treat both BD and comorbid psychiatric conditions (eg, anxiety). Thus, polypharmacy with BD is the norm. Given the chronic nature of BD and the importance of treatment [4] to quality of life [5], understanding factors associated with medication adherence is integral to clinical management and long-term well-being.

    Medication Adherence

    Across mental health conditions, various common factors affect medication adherence, including the number and type of medications prescribed. Clinicians generally strive for monotherapy, as a single medication enables better adherence compared to multidrug regimens; the more drugs prescribed, the lower the medication adherence [6]. Also, drugs taken multiple times a day have lower adherence compared to those taken once a day or less [6]. Number and severity of side effects also reduce medication adherence [2,7]. Germane to BD, cognitive decline is associated with lower adherence due to various factors (eg, forgetfulness and misplacing medication).

    Medication adherence is closely associated with the symptoms of the underlying condition as adherence both affects, and is affected by, symptoms. With physical health conditions, adherence increases with the onset of symptoms. With mental health conditions, however, associations between symptoms and adherence are more complex. With BD, the range and contrary effects of symptoms further affect adherence. During manic episodes, for instance, patients can experience euphoria and omnipotence, and do not see themselves as unwell; on the contrary, this anosognosia, or lack of symptom insight, predicts poor medication adherence. While euthymic or while experiencing psychosis or manic symptoms, persons with BD may consciously discontinue pharmacotherapy [8,9].

    Existing research suggests that predictors of poor medication adherence with BD include severity and type of symptoms (both depression and hypo/mania; hypomania + mania = hypo/mania: a continuum where the point of transition is not always apparent), various sociodemographic factors (eg, education), substance misuse, medication regimen, and therapeutic relationship [10-13]. Generally, persons with BD report relatively low medication adherence [14]; in fact, adherence is poor for 20% to 60% of adults with BD [12]. This is problematic for clinical management of a chronic mental health condition with severe symptoms (eg, self-harm) [15] and effective pharmacotherapy [16].

    For this study, we set out to identify both direct and indirect predictors of medication adherence with BD. Multivariate analyses included both psychiatric and psychosocial factors. Medication adherence was also compared across BD subtypes, country of residence, and prescription of lithium versus other mood stabilizers.


    Ethics Approval

    Ethics approval for the BADAS (Bipolar Affective Disorder and older Adults) study was received from the Human Ethics Research Committee at Simon Fraser University (2014s0375).

    Recruitment and Data Collection

    For the BADAS study, an international sample of young and older adults with BD was recruited using microtargeted Facebook advertising [17-19]. Recruitment notices were sent only to those with “BD interests” (a euphemism used by Facebook to avoid diagnostic labels). Machine-generated algorithms calculated by social media platforms are distinctive not so much for their sensitivity but for their specificity (ie, exclusion of those who do not have BD). That is, participants recruited via social media are not representative of the population; in fact, they may be more symptomatic than BD outpatients attending mood disorder clinics [20], yet we can be confident that the participants were persons with BD, as only Facebook users with BD received recruitment notices [21]. In previous research in which participants with BD were recruited via Facebook, diagnoses were confirmed in clinical interviews [22,23] and corroborated by cohabiting partners (ie, proxy informants) [18].

    By clicking on advertisements appearing within Facebook newsfeeds or sidebar, participants were directed to an online form that specified study inclusion criteria [21]. Thereafter, they completed counterbalanced questionnaires on a secure server; responses were encrypted before transmission [24].

    Participants completed 2 sets of online questionnaires an average of 67 (SD 18) days apart. BD symptoms were measured at both points of measurement. In the second wave, we also measured BD medication, adherence, and current symptom levels (both depression and hypo/mania).

    Most participants (N=92) indicated that they were currently prescribed 1 or more mood stabilizer (n=54, 59%) and ≥1 antidepressant (n=59, 64%); smaller numbers listed 1 or more anxiolytic (n=36, 39%) and 1 or more antipsychotic (n=35, 38%). By category, lithium (n=78), bupropion (n=43), clonazepam (n=55), and quetiapine (n=68) were the medications most listed by participants (ie, mood stabilizer, antidepressant, anxiolytic, and antipsychotic, respectively).

    Participants were also asked to categorize each of these medications: 96% (88/92) correctly specified and categorized both mood stabilizers and anxiolytics, 97% (89/92) for antidepressants, and 86% (79/92) for antipsychotics. This high level of accuracy fosters confidence that participants were, in fact, persons with BD, who were informed about their condition and treatment.

    Instruments

    The 8-item Morisky Medication Adherence Scale (MMAS-8) is a self-report scale widely used across settings and clinical populations [25]. Factors known to be associated with MMAS-8 responses by BD patients include depressive symptoms, socioeconomic status, family support, alcohol consumption [26], and belief in the efficacy of treatment [27]. Test-retest reliability over 2 weeks has been reported as r=0.72 [28]. MMAS-8 responses strongly correlate with the Medication Adherence Report Scale (r=0.56), suggesting concurrent validity [29].

    The Bipolar Disorder Symptom Scale (BDSx) [30,31] was developed to measure symptoms of both depression and hypo/mania. Respondents indicate the degree to which 20 mood adjectives correspond to how they feel at that moment. Responses are provided on a Likert scale ranging from not at all (0) to a lot (2). Elevated responses to both depression and hypo/mania subscales correspond to blind psychiatric diagnoses of depressive and hypo/manic mood episodes [1].

    The construct validity of the BDSx is supported by quality of life with BD [20], across BD subtypes [32], and by responses from cohabiting partners [18]. For instance, affrontive symptoms of hypo/mania appear to have the greatest negative impact on partners, especially when couples are physically together (GPS coordinates) [18].

    The Alcohol Use Disorders Identification Test (AUDIT) [33] is a 10-item self-report questionnaire measuring alcohol consumption. The internal consistency of AUDIT responses is within acceptable parameters (.74<α<.96). Concurrent validity has been demonstrated relative to the Michigan Alcoholism Screening Test (r=0.77) [34]. Research using the AUDIT suggests that cognitive loss is greater for BD patients with concomitant alcohol use disorders [35].

    The 17-item Cognitive Failures Questionnaire (CFQ) [36] measures subjective or perceived failures in perception, memory, and motor function. CFQ responses correlate positively with accident proneness, human error, and psychological strain, and negatively with executive functioning [37]. CFQ responses have been validated in general samples [38] and older adults with BD [20]. CFQ responses might be an early indicator of neurodegeneration perceived by patients before objective measurement [39].

    The Spiritual Index of Well-Being (SiWB) was developed for health-related quality of life research with various clinical populations [40]. Test-retest reliability has been reported as r=0.78 over 2 weeks. Good internal consistency has been reported with various adult populations (.84<α<.90) [40].

    The SiWB does not measure religiosity, but self-efficacy (α=.86) and life scheme (α=.86) [41]. In essence, the SiWB is a measure of psychological well-being. Responses to the SiWB are strongly correlated with self-transcendence (r=0.59), supporting the construct validity of the scale [41]. Among older adults, SiWB responses strongly correlate with both optimism (r=0.51) and meaning in life (r=0.46) [42]. SiWB responses are inversely correlated with depression in primary care [43]. Spirituality and religiosity appear related to quality of life over time with BD [44].

    A sociodemographic questionnaire was constructed to collect descriptive and mental health information. Participants indicated their country of residence (from a drop-down menu); number of years of education; work or occupation; current employment; and relationship status. At recruitment, they were asked if they had BD and subtype, if known; at time 2, they were asked if they had been diagnosed with BD by a clinician (eg, psychiatrist) and date of BD diagnosis (month and year). We included only those who indicated that they both had BD and had been diagnosed with BD.

    Statistical Methods

    Path analysis was performed for this study as a three-step process [45]. A hypothesized model was first tested in which all independent variables were assumed to directly predict medication adherence, nonsignificant paths were deleted, and statistically significant paths not initially hypothesized were added if supported by existing research or theory.

    Path analysis is an extension of linear regression with three significant advantages [45]. Path analysis allows us to simultaneously predict one or more dependent variables (touched by arrowheads in path models). Arrows pointing from independent to dependent variables represent significant prediction (ie, critical ratio [CR] values >|1.96|, P<.05). Path analysis is a multivariate statistical procedure, meaning that all significant paths emerge concurrently (ie, over and above other statistically significant results).

    Path models allow us to identify both direct and indirect predictors of medication adherence [45]. Indirect prediction occurs via other variables (ie, ≥2 pathways between variables). In complex or more nuanced path models, variables can have direct and indirect effects on dependent variables, and indirect effects can be of equal or greater magnitude than direct effects (total effects = direct + indirect effects).

    Computing path analyses with structural equation modeling software allows us to obtain goodness of fit information for the overall model. Good model fit is required to interpret path models [46]. In accord with convention, we report three goodness-of-fit-indices to assess overall model fit of path models to data: an incremental (comparative fit index [CFI]), an absolute (standardized root mean residual [SRMR]), and a parsimonious (root mean square error of approximation [RMSEA]) fit index. Ideal SRMR and RMSEA values are less than 0.055, whereas ideal CFI values are greater than 0.95 [45].

    Descriptive and comparative analyses were performed using SPSS (version 28; IBM Corp) and path analyses were performed using AMOS (version 26; IBM Corp).


    Descriptive Features

    For this study, 92 BADAS participants were identified who reported medication information and medication adherence (mean age 55.35, SD 9.65 years). Their age ranged from 22 to 73 years; there were 35 men and 57 women. On average, participants had been diagnosed with BD 14.25 (SD 11.14) years ago. They were currently prescribed an average of 2.40 (SD 1.28; range 0-6) psychotropic medications. Descriptive statistics for study variables are reported in Table 1.

    Table 1. Descriptive statistics and study variables (N=92).

    		Men, mean (SD)Women, mean (SD)αt (df)P value
    Age (years)56.48 (9.33)54.94 (9.86)—a0.72 (85).47
    Education (years)11.33 (6.06)11.06 (5.77)—0.21 (84).83
    Duration of bipolar disorder diagnosis (years)13.78 (12.40)14.59 (10.44)—–0.30 (81).77
    Comorbid psychiatric conditions, n0.73 (1.10)0.96 (1.21)—–0.91 (85).37
    Total psychotropic prescriptions, n2.18 (1.24)2.48 (1.34)—–1.01 (85).30
    Morisky Medication Adherence Scale (score)7.22 (1.61)6.41 (2.81).70–1.74 (85).09
    Bipolar Disorder Symptom Scale (BDSx; score)

    		Depression8.06 (5.20)10.17 (5.79).91–1.71 (85).09

    		Hypo/mania4.27 (3.81)4.83 (4.20).83–0.63 (85).53
    Spiritual Index of Well-Being (score)38.88 (12.99)34.44 (10.65).941.73 (85).10
    Alcohol Use Disorders Identification Test (score)4.91 (4.98)4.50 (5.65).860.34 (85).73
    Cognitive Failures Questionnaire (score)48.24 (19.51)56.72 (19.81).951.95 (85).06

    aNot applicable.

    Most participants lived in North America (Canada: n=30, United States: n=30) with the remainder living in the UK or Ireland (n=22), Australia or New Zealand (n=8), or continental Europe (n=2); n=5 did not specify. They had completed an average of 11.16 (SD 5.85; range 1-22) years of education. The plurality worked in managerial/professional (n=25) or administrative/clerical positions (n=22); 21 were currently retired or receiving a disability pension. Almost all participants were White (82/92, 89%).

    Of those reporting a BD subtype, a plurality specified a BD II diagnosis (n=31), followed by BD not otherwise specified (n=21) and BD I (n=14). Consistent with BD prevalence data [47], few indicated that they had been diagnosed with cyclothymic disorder (n=6). Reported medication adherence did not differ by BD subtype (F3,68=0.20; P=.89), nor did adherence differ between those prescribed lithium carbonate versus other mood stabilizers (eg, valproic acid; t51=0.63; P=.53). Also of note, adherence did not differ between those concurrently prescribed both a mood stabilizer and an antidepressant versus one or more mood stabilizers alone (ie, no antidepressants; t90=1.76; P=.08).

    The relative frequency of BD subtypes did not differ by country of residence (χ26=3.10; P=.80), nor was lithium more widely prescribed in one region than others (χ26=4.72; P=.58). More participants in North America were prescribed one or more antidepressants (50/60, 83%) than those in western Europe (15/22, 68%) or Australia and New Zealand (4/8, 50%), but this difference is not statistically significant (χ22=5.56; P=.06). Medication adherence also did not differ by country (F2,87=0.32; P=.73).

    Moreover, medication adherence was not associated with age (r=0.13; P=.23) or duration of BD diagnosis (r=0.10; P=.38). A small inverse association emerged between adherence and number of psychotropic medications (r=–0.26; P=.01).

    Path Analyses

    We computed path analyses to identify both direct and indirect predictors of medication adherence with BD. We hypothesized that psychological well-being and BD symptoms (both depression and hypo/mania) would significantly predict medication adherence. The number of psychotropic medications, alcohol misuse, and perceived cognitive failures were also assumed to predict adherence. A sample of 92 participants is small but sufficient to detect medium to large effect sizes with 5 to 6 independent variables, where α=.05 and d=.80 [48].

    Goodness of fit was within optimal parameters for two of three statistics examined (χ213=11.17; P=.60). The comparative fit index (CFI≥0.95; CFI=0.99) and the root mean square error of approximation (RMSEA≤0.05; RMSEA=0.001) were both within ideal parameters (0<RMSEA 90% confidence limits <0.091); whereas the standardized root mean square residual was adequate (SRMR≤0.080; SRMR=0.075).

    A more nuanced model emerged than hypothesized. More precisely, only alcohol misuse and perceived cognitive failures emerged as direct predictors of medication adherence; their relative magnitude is similar (ie, β=–.23 and β=–.28, respectively). Neither symptoms of depression nor hypo/mania emerged as direct predictors of medication adherence; instead, both are predicted by psychosocial factors, which directly and indirectly predict medication adherence. Perceived cognitive failures predict symptoms of depression (β=.47, P<.01), hypo/mania (β=.42, P<.01), and the absence of psychological well-being (β=–.52, P<.01). Number of comorbid psychiatric conditions is also inversely associated with psychological well-being (β=–.24, P<.01).

    Alcohol misuse predicts medication adherence, not psychological well-being, BD symptoms, or perceived cognitive failures. Age is not associated with cognitive failures (r=0.13, P=.23). This finding is noteworthy given the 51-year age range of participants (22-73 years). Prior research has identified perceived cognitive failures as significantly associated with quality of life for older adults with BD [14]. The results of this study suggest that perceived cognitive failures are not exclusive to later life with BD.

    Direct and Indirect Effects

    As shown in Figure 1 and Table 2, the number of comorbid psychiatric conditions indirectly predicts both symptoms of depression and hypo/mania via psychological well-being. Also, perceived cognitive failures directly and indirectly predict depression and hypo/mania, again via psychological well-being. Of note, the effect of cognitive failures on hypo/mania is bidirectional. A positive direct effect emerged between perceived cognitive failures and symptoms of hypo/mania, which is negated somewhat by a negative indirect effect via psychological well-being. This positive association between hypo/mania and well-being is contrary to prior research suggesting no association between symptoms of hypo/mania and life satisfaction [49].

    ‎
    Figure 1. Note: Parameters expressed as maximum likelihood estimates (standardized solution). Parenthetical numbers indicate significance levels (CR > |1.96|, P<.05; CR > |2.58|, P<.01). Sx: symptoms.
    View this figure
    Table 2. Direct, indirect, and total variance explained.

    		Comorbid ConditionsCognitive failuresAlcohol misuseWell-being
    Well-being

    		Direct–0.24–0.52


    		Indirect00


    		Totala–0.24–0.52

    Medication adherence

    		Direct
    		–0.28–0.23

    		Indirect
    		00

    		Total
    		–0.28–0.23
    Hypo/mania symptoms

    		Direct00.42
    		0.33

    		Indirect–0.08–0.17
    		0

    		Total–0.080.25
    		0.33
    Depression symptoms

    		Direct00.47
    		–0.31

    		Indirect0.070.16
    		0

    		Total0.070.63
    		–0.31

    aTotal values are a sum of direct and indirect values presented in the two immediately preceding rows.


    Principal Findings

    For this study, we identified an international sample of young and older adults with BD. Few differences emerged in medication adherence across regions, medications, or BD subtypes. Most participants in North America were prescribed an antidepressant in contrast to other regions, but this difference did not attain statistical significance.

    Alcohol misuse and perceived cognitive failures both emerged as significant direct predictors of medication adherence. Number of comorbid psychiatric conditions, psychological well-being, and BD symptoms emerged as indirect predictors via cognitive failures. This finding is in accord with existing research indicating that perceived cognitive failures are significant predictors of quality of life among older adults with BD [20].

    BD symptoms, both depression and hypo/mania, are significantly associated with perceived cognitive failures when reported contemporaneously; this effect appears to be both direct and indirect (via psychological well-being). Of note, the direction of direct versus indirect effects differs between cognitive failures and hypo/mania. That is, perceived cognitive failures significantly and directly predict symptoms of hypo/mania, yet the indirect effect via psychological well-being is negative. This suggests that different BD symptoms are associated with certain types of perceived cognitive failures and not others. This bidirectional association underscores the importance of examining both direct and indirect effects in path analyses, not just total variance explained.

    These findings are somewhat in accord with previously published research. For instance, certain BD-related factors (ie, number of comorbid psychiatric conditions) emerged as indirectly associated with medication adherence. Our findings corroborate other research demonstrating an inverse relationship between alcohol misuse and medication adherence [10]. However, we found no associations between type of medication regimen and adherence [11]; nor did current BD symptoms, either depression or hypo/mania, directly predict medication adherence [12].

    Also noteworthy are factors that appear unrelated to medication adherence, such as medication regimen, duration of diagnosis, and age. The latter finding is noteworthy given the 51-year age range of participants; that is, persons in their 20s with BD reported similar levels of medication adherence and cognitive failures as those in their 60s. This suggests that perceived cognitive loss is a facet of adult life for many with BD, in contrast to the assumption that accelerated cognitive aging with BD begins in midlife [50,51]. Further study is required.

    Limitations and Future Research

    A primary limitation of this study is measurement of medication adherence by self-report only. Though the MMAS-8 has been well studied, including BD [52], adherence is complicated to measure, especially with mental health conditions expressed by affective symptoms rather than objective markers. Further measurement of adherence using other methods (eg, pharmacy records) shoould corroborate self-reported responses.

    The same is true for self-reported cognitive errors, which are not strongly correlated with performance on neurocognitive test batteries. This has led some to question the validity and utility of self-reported cognitive deficits. It has been suggested that self-reported cognitive deficits are unrelated to well-being with BD [53,54]. This assumption is challenged by an initial BADAS study reporting that perceived cognitive failures directly and indirectly predicted suicide ideation in older adults with BD [20]. Self-reported or perceived cognitive deficits may not reflect neuropsychological test scores, yet more research is needed to better understand associations with adherence.

    The results of this study need to be replicated with larger samples and over time. Our sample was sufficient to compute a path model with 6 independent variables; a larger sample may have enabled us to detect small effect sizes and more distal predictors of medication adherence with BD. The direction of cross-sectional associations reported herein may have differed if associations had been measured over time. For instance, poor medication adherence may well predict future symptoms of both depression and hypo/mania; that contemporaneous association was not found. Repeated data collection over an extended interval is needed to more fully understand factors associated with medication adherence with BD. This includes recruitment of participants with BD using more traditional methods (ie, recruitment at mood disorder clinics).

    Despite these limitations, we were able to recruit an international sample of young and older adults with BD sufficient for comparative and path analyses. This allowed us to identify both direct and indirect predictors of medication adherence. Our model includes BD symptoms (both depression and hypo/mania), comorbid psychiatric conditions, psychological well-being, and alcohol misuse. When examined contemporaneously, perceived cognitive failures appear most strongly associated with adherence with BD.

    Summary

    BD is a chronic mental health condition with onset in early life that persists across adult life. Despite the severity of symptoms and efficacy of pharmacotherapy, medication adherence by many with BD is problematic [12,14]. The results of this study suggest that cognitive failures and alcohol misuse are direct predictors of poor adherence. BD symptoms appear to affect medication adherence via bidirectional effects upon other variables.

    Acknowledgments

    Support for this study was provided by the Age-Well Network of Centres for Excellence (CRP 2015-WP6.2; NO’R) and the Institutes of Aging of the Canadian Institutes of Health Research (RN 134209–259022) awarded to NO’R and AS. Portions of this study were presented at the European Congress on Psychiatry (June 2022), Budapest, Hungary/online.

    Conflicts of Interest

    None declared.

    1. Osher Y, Bersudsky Y, O'Rourke N, Belotherkovsky D, Bachner YG. Clinical validation of the BDSx scale with bipolar disorder outpatients. Arch Psychiatr Nurs 2020 Mar;34(1):49-52. [CrossRef] [Medline]
    2. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv 2008 Oct;59(10):1175-1183. [CrossRef] [Medline]
    3. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20(1):29-42. [CrossRef] [Medline]
    4. Corréard N, Consoloni J, Raust A, Etain B, Guillot R, Job S, FACE-BD collaborators. Neuropsychological functioning, age, and medication adherence in bipolar disorder. PLoS One 2017;12(9):e0184313 [FREE Full text] [CrossRef] [Medline]
    5. Gutiérrez-Rojas L, Gurpegui M, Ayuso-Mateos JL, Gutiérrez-Ariza JA, Ruiz-Veguilla M, Jurado D. Quality of life in bipolar disorder patients: a comparison with a general population sample. Bipolar Disord 2008 Jul;10(5):625-634. [CrossRef] [Medline]
    6. Usherwood T. Encouraging adherence to long-term medication. Aust Prescr 2017 Aug;40(4):147-150 [FREE Full text] [CrossRef] [Medline]
    7. Bowskill R, Clatworthy J, Parham R, Rank T, Horne R. Patients' perceptions of information received about medication prescribed for bipolar disorder: implications for informed choice. J Affect Disord 2007 Jun;100(1-3):253-257 [FREE Full text] [CrossRef] [Medline]
    8. García S, Martínez-Cengotitabengoa M, López-Zurbano S, Zorrilla I, López P, Vieta E, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic review. J Clin Psychopharmacol 2016 Aug;36(4):355-371 [FREE Full text] [CrossRef] [Medline]
    9. Colom F, Vieta E, Martínez-Arán A, Reinares M, Benabarre A, Gastó C. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000 Aug;61(8):549-555. [CrossRef] [Medline]
    10. Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007 Oct 01;2:29 [FREE Full text] [CrossRef] [Medline]
    11. Crowe M, Wilson L, Inder M. Patients' reports of the factors influencing medication adherence in bipolar disorder - an integrative review of the literature. Int J Nurs Stud 2011 Jul;48(7):894-903. [CrossRef] [Medline]
    12. Levin JB, Krivenko A, Howland M, Schlachet R, Sajatovic M. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs 2016 Sep;30(9):819-835. [CrossRef] [Medline]
    13. Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry 2015 Aug 05;15:189 [FREE Full text] [CrossRef] [Medline]
    14. Consoloni J, M'Bailara K, Perchec C, Aouizerate B, Aubin V, Azorin J, Groupe FACE-BD. Trajectories of medication adherence in patients with bipolar disorder along 2 years-follow-up. J Affect Disord 2021 Mar 01;282:812-819. [CrossRef] [Medline]
    15. O'Rourke N, Heisel MJ, Canham SL, Sixsmith A, BADAS Study Team. Predictors of suicide ideation among older adults with bipolar disorder. PLoS One 2017;12(11):e0187632 [FREE Full text] [CrossRef] [Medline]
    16. Osher Y, Bersudsky Y, Belmaker R. The new lithium clinic. Neuropsychobiology 2010;62(1):17-26. [CrossRef] [Medline]
    17. O'Rourke N, Sixsmith A, BADAS Study Team. Ecological momentary assessment of mood and movement with bipolar disorder over time: Participant recruitment and efficacy of study methods. Int J Methods Psychiatr Res 2021 Dec;30(4):e1895 [FREE Full text] [CrossRef] [Medline]
    18. Yerushalmi M, Sixsmith A, Pollock Star A, King DB, O'Rourke N. Ecological momentary assessment of bipolar disorder symptoms and partner affect: longitudinal pilot study. JMIR Form Res 2021 Sep 02;5(9):e30472 [FREE Full text] [CrossRef] [Medline]
    19. Pollock Star A, Bachner YG, Cohen B, Haglili O, O'Rourke N. Social Media Use and Well-being With Bipolar Disorder During the COVID-19 Pandemic: Path Analysis. JMIR Form Res 2022 Aug 18;6(8):e39519 [FREE Full text] [CrossRef] [Medline]
    20. O'Rourke N, Sixsmith A, Kirshner G, Osher Y. Perceived cognitive failures and quality of life for older adults with bipolar disorder. J Affect Disord 2021 May 15;287:433-440. [CrossRef] [Medline]
    21. King DB, O'Rourke N, DeLongis A. Social media recruitment and online data collection: A beginner’s guide and best practices for accessing low-prevalence and hard-to-reach populations. Canadian Psychology / Psychologie canadienne 2014 Nov;55(4):240-249. [CrossRef]
    22. Canham SL, Mahmood A, Stalman MN, King D, O'Rourke N. Personal theories of substance use among middle-aged and older adults with bipolar disorder. Aging Ment Health 2018 Jun;22(6):813-818. [CrossRef] [Medline]
    23. Stalman MN, Canham SL, Mahmood A, King D, O'Rourke N. Aspects of control and substance use among middle-aged and older adults with bipolar disorder. Int J Ment Health Nurs 2018 Apr;27(2):833-840. [CrossRef] [Medline]
    24. King DB, Sixsmith A, Shahir HY, Sadeghi M, Razmara M, O’Rourke N. An ecological momentary sampling tool for movement patterns and psychiatric symptom variability: A pilot study. Gerontechnology 2016;14(2):105-109 [FREE Full text] [CrossRef]
    25. Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986 Jan;24(1):67-74. [CrossRef] [Medline]
    26. Barraco A, Rossi A, Nicolò G, EPHAR Study Group. Description of study population and analysis of factors influencing adherence in the observational Italian study "Evaluation of Pharmacotherapy Adherence in Bipolar Disorder" (EPHAR). CNS Neurosci Ther 2012 Mar;18(2):110-118 [FREE Full text] [CrossRef] [Medline]
    27. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol 2011 Mar;64(3):255-7; discussion 258 [FREE Full text] [CrossRef] [Medline]
    28. Salt E, Hall L, Peden AR, Home R. Psychometric properties of three medication adherence scales in patients with rheumatoid arthritis. J Nurs Meas 2012;20(1):59-72. [CrossRef] [Medline]
    29. Horne R, Weinman J, Barber N, Elliott R, Morgan M, Cribb A, et al. Concordance, adherence and compliance in medicine taking. NCCSDO 2005 Dec:40-46 [FREE Full text]
    30. O'Rourke N, Sixsmith A, King DB, Yaghoubi-Shahir H, Canham SL, BADAS Study Team. Development and validation of the BDSx: A brief measure of mood and symptom variability for use with adults with bipolar disorder. Int J Bipolar Disord 2016 Dec;4(1):8 [FREE Full text] [CrossRef] [Medline]
    31. O'Rourke N, Bachner YG, Canham SL, Sixsmith A, BADAS Study Team. Measurement equivalence of the BDSx scale with young and older adults with bipolar disorder. Psychiatry Res 2018 May;263:245-249. [CrossRef] [Medline]
    32. O'Rourke N, Sixsmith A, Michael T, Bachner YG. Is the 4-factor model of symptomology equivalent across bipolar disorder subtypes? Int J Bipolar Disord 2021 Aug 02;9(1):24 [FREE Full text] [CrossRef] [Medline]
    33. Babor T, Grant M. From clinical research to secondary prevention: International collaboration in the development of the Alcohol Disorders Identification Test (AUDIT). Alcohol Health Res World 1989;13(4):371-374 [FREE Full text]
    34. Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res 1997 Jun;21(4):613-619. [Medline]
    35. Levy B, Monzani BA, Stephansky MR, Weiss RD. Neurocognitive impairment in patients with co-occurring bipolar disorder and alcohol dependence upon discharge from inpatient care. Psychiatry Res 2008 Oct 30;161(1):28-35 [FREE Full text] [CrossRef] [Medline]
    36. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982 Mar;21(1):1-16. [CrossRef] [Medline]
    37. Banich MT. Executive function: the search for an integrated account. Curr Dir Psychol Sci 2009 Apr 01;18(2):89-94. [CrossRef]
    38. Rast P, Zimprich D, Van Boxtel M, Jolles J. Factor structure and measurement invariance of the cognitive failures questionnaire across the adult life span. Assessment 2009 Jun;16(2):145-158. [CrossRef] [Medline]
    39. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 2012 Oct;50(12):2880-2886 [FREE Full text] [CrossRef] [Medline]
    40. Daaleman TP, Perera S, Studenski SA. Religion, spirituality, and health status in geriatric outpatients. Ann Fam Med 2004 Jan 01;2(1):49-53 [FREE Full text] [CrossRef] [Medline]
    41. López AJ, McCaffrey R, Quinn Griffin MT, Fitzpatrick JJ. Spiritual well-being and practices among women with gynecologic cancer. Oncol Nurs Forum 2009 May;36(3):300-305. [CrossRef] [Medline]
    42. Elkady AA. Comparative study of self-transcendence, spiritual wellbeing, optimism and meaning in life among retirees and post-retirement employees. Psycho-Educ Res Rev 2019:85-94. [CrossRef]
    43. Daaleman TP, Kaufman JS. Spirituality and depressive symptoms in primary care outpatients. South Med J 2006 Dec;99(12):1340-1344. [CrossRef] [Medline]
    44. Stroppa A, Colugnati FA, Koenig HG, Moreira-Almeida A. Religiosity, depression, and quality of life in bipolar disorder: a two-year prospective study. Braz J Psychiatry 2018;40(3):238-243 [FREE Full text] [CrossRef] [Medline]
    45. O'Rourke N, Hatcher L. A step-by-step approach to using SAS for factor analysis and structural equation modeling. Cary, NC: SAS Institute; 2013.
    46. Byrne B. Structural equation modeling with AMOS: basic concepts, applications, and programming (3rd ed.). Milton Park, UK: Routledge; 2016.
    47. Van Meter AR, Youngstrom EA, Findling RL. Cyclothymic disorder: a critical review. Clin Psychol Rev 2012 Jun;32(4):229-243. [CrossRef] [Medline]
    48. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.). Milton Park, UK: Routledge; 2013.
    49. Meyer C, Rumpf H, Hapke U, John U. Impact of psychiatric disorders in the general population: satisfaction with life and the influence of comorbidity and disorder duration. Soc Psychiatry Psychiatr Epidemiol 2004 Jun;39(6):435-441. [CrossRef] [Medline]
    50. Delaloye C, Moy G, de Bilbao F, Weber K, Baudois S, Haller S, et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. Int J Geriatr Psychiatry 2011 Dec;26(12):1309-1318. [CrossRef] [Medline]
    51. Gildengers AG, Chisholm D, Butters MA, Anderson SJ, Begley A, Holm M, et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression? Psychol Med 2013 Apr;43(4):801-811 [FREE Full text] [CrossRef] [Medline]
    52. Chauhan N, Chakrabarti S, Grover S. Identifying poor adherence in outpatients with bipolar disorder: a comparison of different measures. J Neurosci Rural Pract 2022 Jan;13(1):12-22 [FREE Full text] [CrossRef] [Medline]
    53. Cardoso T, Bauer IE, Meyer TD, Kapczinski F, Soares JC. Neuroprogression and cognitive functioning in bipolar disorder: a systematic review. Curr Psychiatry Rep 2015 Sep;17(9):75. [CrossRef] [Medline]
    54. Schouws SNTM, Korten N, Beekman ATF, Stek ML, Dols A. Does cognitive function in older bipolar patients depend on recurrent or current mood symptoms? Int J Geriatr Psychiatry 2020 Oct;35(10):1163-1170. [CrossRef] [Medline]

    ‎
    AUDIT: Alcohol Use Disorders Identification Test
    BADAS: Bipolar Affective Disorders and older Adults Study
    BD: Bipolar disorder
    BDSx: Bipolar Disorder Symptom Scale
    CFI: comparative fit index
    CFQ: Cognitive Failures Questionnaire
    CR: critical ratio
    MMAS-8: Morisky Medication Adherence Scale
    RMSEA: root mean square error of approximation
    SiWB: Spiritual Index of Well-Being
    SRMR: standardized root mean residual

    Edited by A Mavragani; submitted 04.11.22; peer-reviewed by A AL-Asadi, P Harvey; comments to author 21.12.22; revised version received 24.12.22; accepted 27.12.22; published 07.02.23

    Copyright

    ©Bar Cohen, Andrew Sixsmith, Ariel Pollock Star, Ophir Haglili, Norm O'Rourke. Originally published in JMIR Formative Research (https://formative.jmir.org), 07.02.2023.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.